JP2025508066A5 - - Google Patents

Info

Publication number
JP2025508066A5
JP2025508066A5 JP2024553409A JP2024553409A JP2025508066A5 JP 2025508066 A5 JP2025508066 A5 JP 2025508066A5 JP 2024553409 A JP2024553409 A JP 2024553409A JP 2024553409 A JP2024553409 A JP 2024553409A JP 2025508066 A5 JP2025508066 A5 JP 2025508066A5
Authority
JP
Japan
Application number
JP2024553409A
Other languages
Japanese (ja)
Other versions
JPWO2023170474A5 (https=
JP2025508066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/000124 external-priority patent/WO2023170474A1/en
Publication of JP2025508066A publication Critical patent/JP2025508066A/ja
Publication of JPWO2023170474A5 publication Critical patent/JPWO2023170474A5/ja
Publication of JP2025508066A5 publication Critical patent/JP2025508066A5/ja
Pending legal-status Critical Current

Links

JP2024553409A 2022-03-07 2023-03-07 目的としたt細胞活性化のためのcd28二重特異性抗体 Pending JP2025508066A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263317491P 2022-03-07 2022-03-07
US63/317,491 2022-03-07
US202263323893P 2022-03-25 2022-03-25
US63/323,893 2022-03-25
PCT/IB2023/000124 WO2023170474A1 (en) 2022-03-07 2023-03-07 Cd28 bispecific antibodies for targeted t cell activation

Publications (3)

Publication Number Publication Date
JP2025508066A JP2025508066A (ja) 2025-03-21
JPWO2023170474A5 JPWO2023170474A5 (https=) 2026-03-17
JP2025508066A5 true JP2025508066A5 (https=) 2026-03-17

Family

ID=86272440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553409A Pending JP2025508066A (ja) 2022-03-07 2023-03-07 目的としたt細胞活性化のためのcd28二重特異性抗体

Country Status (8)

Country Link
US (1) US20240002544A1 (https=)
EP (1) EP4490192A1 (https=)
JP (1) JP2025508066A (https=)
CN (1) CN119233993A (https=)
AU (1) AU2023232992A1 (https=)
CA (1) CA3249273A1 (https=)
IL (1) IL314916A (https=)
WO (1) WO2023170474A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212599A1 (en) * 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合
WO2024084052A1 (en) 2022-10-21 2024-04-25 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2025051895A1 (en) * 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
TW202544034A (zh) * 2024-05-06 2025-11-16 美商榮都醫療公司 結合至cd28及nectin-4之雙特異性抗體
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
PT2171060E (pt) 2004-11-11 2013-11-18 Theramab Llc Anticorpo anti-cd28 superagonista
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
RS56793B1 (sr) 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
MX375359B (es) 2013-02-26 2025-03-06 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de células t.
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JP7220161B2 (ja) * 2017-05-26 2023-02-09 ノビミューン エスアー 抗CD47x抗メソテリン抗体およびそれを使用する方法
JP2020527158A (ja) * 2017-07-21 2020-09-03 ノビミューン エスアー 多重特異性抗体混合物の生成およびその使用方法
EP3802599B1 (en) * 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2019246514A1 (en) 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
US11453721B2 (en) 2018-12-19 2022-09-27 Regeneran Pharmaceuticals, Inc. Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
JP2022513495A (ja) 2018-12-21 2022-02-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍標的化スーパーアゴニストcd28抗原結合分子
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
WO2020198009A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. EGFR x CD28 MULTISPECIFIC ANTIBODIES
CN114786776B (zh) 2019-09-18 2026-03-24 拉姆卡普生物阿尔法股份公司 针对ceacam5和cd3的双特异性抗体
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
CN115702168A (zh) 2020-06-23 2023-02-14 豪夫迈·罗氏有限公司 靶向Her2的激动性CD28抗原结合分子
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
ES2967381T3 (es) * 2020-12-18 2024-04-30 Lamkap Bio Beta Ag Anticuerpos biespecíficos contra CEACAM5 y CD47

Similar Documents

Publication Publication Date Title
JP2025508066A5 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13140U (https=)
BY23963C1 (https=)
BY13169U (https=)
CN307045619S (https=)
CN307045556S (https=)
CN307045946S (https=)
CN307045518S (https=)
CN307046332S (https=)
CN307047054S (https=)
CN307045040S (https=)
BY13168U (https=)